DPP4 inhibitors and SGLT2 inhibitors are widelyused therapies for T2D that are associated with a low incidence of hypoglycemia, with DPP4 inhibitors being body-weight neutral (4) and SGLT2 inhibitors promoting weight loss and also reducing systolic blood pressure (SBP) (5-8). Here, SLC5A2 is linked to Hypoglycemia.